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Running title: PROVETS – Definitions and data reporting 
 
Abbreviations: 
: alpha angle (TEG variable) 
CFT: clot formation time (ROTEM variable) 
CT: clotting time (ROTEM variable) 
EPL: estimated percentage lysis (TEG variable) 
G: shear elastic modulus or global clot strength (TEG variable) 
K: kappa value (TEG variable) 
LOE: level of evidence 
LOT: lysis onset time (ROTEM variable) 
LT: lysis time (ROTEM variable) 
MA: maximum amplitude (TEG variable) 
MCE: maximum clot elasticity or shear elastic modulus (ROTEM variable) 
MCF: maximum clot firmness (ROTEM variable) 
ML: maximum lysis (ROTEM variable) 
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R: reaction time (TEG variable) 
ROTEM: rotational thromboelastometry 
TEG: thromboelastography 
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Abstract 
Objective: To systematically examine evidence surrounding definitions and reporting of 
data for viscoelastic testing in veterinary medicine.  
Design: Standardized, systematic evaluation of the literature, categorization of relevant 
articles according to level of evidence and quality, and development of consensus on 
conclusions for application of the concepts to clinical practice. 
Setting: Academic and referral veterinary medical centers.  
Results: Databases searched included Medline, CAB abstracts, and Google Scholar. 
Conclusions: All 4 standard thromboelastography (TEG) and rotational 
thromboelastometry (ROTEM) variables should be universally reported, and the reporting 
of shear elastic modulus in addition to maximum amplitude (MA) is encouraged. There is 
insufficient evidence to support universal usage of the coagulation index at this time. The 
K value and clot formation time are the most variable of the 4 parameters, with alpha angle, 
MA, and maximum clot firmness generally the least variable. Individual studies should 
report sufficient data on patients and institutional controls to enable definitions of hypo- 
and hypercoagulability to be evaluated post-hoc, and it is recommended that all studies 
specifically report how these conditions were defined. In reporting data relating to 
fibrinolysis, the TEG variables Ly30, Ly60, CL30, CL60 and the ROTEM variables LI30, 
LI60, ML, LOT and LT should be documented. Studies should report sufficient data on 
patients and controls to enable definitions of hyper- and hypofibrinolysis to be evaluated 
post-hoc, and we suggest that standard TEG/ROTEM assays may be unable to detect 
hypofibrinolysis in companion animals. We recommend that every center establish 
reference intervals, which are specific to either TEG or ROTEM. These reference intervals 
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should be established using veterinary clinical pathology guidelines, standardized 
protocols, and a minimum of 40 healthy animals. There is currently insufficient data in 
companion animals to suggest a utility for Vcurve variables beyond that of standard TEG 
variables. 
 
Keywords: thromboelastometry, thromboelastography, dog, cat 
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Introduction 
There are currently 2 main systems, the TEG and ROTEM, utilizing viscoelastic 
technology to evaluate hemostasis. Most current laboratory and clinical research in human 
and veterinary medicine has been generated using these systems. The differences between 
these methodologies and the influence of pre-analytical and analytical variables on these 
assays have been presented in the previous three domains. The focus of this domain is to 
define existing variables and summarize available evidence regarding the reporting of data.  
 
Evidence Summary 
Worksheet Question: Should the TEG derived MA value be converted into the G value? 
Conclusions: All 4 standard TEG/ROTEM variables should be universally reported, 
enabling post-hoc calculation of G if required. The reporting of G in addition to MA is 
encouraged to allow authors to evaluate and compare the clinical utility of both variables. 
Summary of evidence: The MA is the maximum amplitude, or width of divergence, of a 
tracing derived via TEG and represents the overall clot strength. The major contributors to 
MA are platelets, followed by fibrinogen, thrombin, factor XIII, and hematocrit. The shear 
elastic modulus, denoted by G, also represents the “global” clot strength and is derived 
from the MA using the following formula: G = (5000 X MA) / (100-MA). Since G is 
derived from the MA, it is a function of the same constituents. However, MA is a linear 
value expressed in mm, while G is an exponential transformation of MA expressed in 
dyn/cm2. Consider that a change in MA from 55 to 70 mm (a 30% change) represents a 
change in G from 5,500 to 11,666 dyn/cm2 (a 112% increase). This distribution has been 
proposed to be more sensitive to hemostatic changes, especially as MA increases in size.  
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Twenty articles were identified which report G in addition to MA. Six studies were 
evaluated which reported both G and MA and included some comparison or discussion of 
the rationale for including the G value (LOE 3-6, Good-Poor).1-6 Of these 6 however, none 
directly addressed the worksheet question. In the 2 veterinary studies, both found MA and 
G to be relatively equal in the dog at identifying patients with clinical bleeding (LOE 4),6 
or patients with hypercoagulability induced by the administration of steroids (LOE 3).2 As 
such a recommendation for using G in addition to, or in place of, MA cannot be made.  
Future Directions: Studies directly comparing the clinical utility of each value against a 
non-TEG outcome measure in companion animals are needed. 
 
Worksheet Question: Which TEG/ROTEM clot formation values should be reported in 
publications? 
Conclusions: We recommend that all 4 standard TEG/ROTEM variables are universally 
reported to enable meta-analyses to be conducted in future. 
Summary of Evidence: Few studies compare the variability or predictive value of the 4 
standard TEG/ROTEM variables. Evidence from 9 studies (4 canine, 3 equine, 2 feline) 
(LOE 2-3, Good),7-15 generally suggests that K time / CFT is the most variable of the 4 
parameters, with  and MA / MCF generally the least variable. This might influence the 
individual predictive utility of the 4 parameters and may need to be considered during 
construction of diagnostic or therapeutic algorithms. No studies specifically compared the 
predictive value of K/CFT versus . A study on biological variation in coagulation 
parameters in dogs (LOE 3, Good),15 suggests that all 4 TEG/ROTEM parameters provide 
useful information about hemostatic potential, as they have a low degree of individuality, 
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making population reference intervals useful for TEG variables.16 This was in contrast to 
clotting times, antithrombin, fibrinogen, and D-dimers which all have a high degree of 
individuality, rendering decisions based on population based reference intervals insensitive 
for those analytes.  
Future Directions: Research comparing the predictive ability of individual TEG/ROTEM 
parameters is required. Until such studies are available, it seems prudent to report all 
TEG/ROTEM parameters to facilitate post-hoc evaluation to be performed and 
comparisons between studies to be made. 
 
Worksheet Question: How should hypercoagulability be defined? 
Conclusions: There is insufficient evidence to recommend how hypercoagulability should 
be defined in companion animals based on TEG/ROTEM parameters at this time. We 
suggest that individual studies report sufficient data on patients and institutional controls 
to enable definitions of hypercoagulability to be evaluated post-hoc. We recommend that 
all studies specifically report how hypercoagulability was defined. We recommend that all 
4 standard TEG/ROTEM variables are universally reported to enable meta-analyses to be 
conducted in future. We recommend that at minimum, contemporaneous values for 
hematocrit, fibrinogen concentration and platelet count be reported in addition to 
TEG/ROTEM results. 
Summary of Evidence: By convention, shortened R (CF) or K (CFT), or increased  or MA 
(MCF), are considered consistent with hypercoagulability in companion animal species. 
Nine articles specific to veterinary companion animals were identified in which a clear 
definition for “hypercoagulability” was presented (LOE 2-6, Fair-Poor).17-25 Two principle 
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strategies for assessing or defining hypercoagulability have been used in the companion 
animal literature to date: 1) comparison of the affected cohort with a control population, 2) 
use of a cut-off value in 1 or more TEG parameters to define hypercoagulability. Cut-off 
values used include the upper bound of the reference intervals for  and MA, the lower 
bounds of R and K times, G values >7200 Kdyn/cm2 or values for these parameters >25% 
above or below the relevant reference interval boundaries. Although these values have been 
used to prognosticate in individual studies, no veterinary studies have compared these 
values with a reliable, independent and objective thrombosis endpoint. As such which 
TEG/ROTEM parameter (if any) should be used to identify hypercoagulability in 
companion animals remains unclear.  
It is also evident from multiple studies in companion animals and humans (LOE 2-
6, Good-Fair),26-32 that several hematologic variables, in particular hematocrit, fibrinogen 
concentration and platelet count, significantly affect the results of TEG/ROTEM assays. 
As such, these values must be considered when defining hypercoagulability in particular 
patient populations, e.g. dogs with IMHA. Values for hematocrit, fibrinogen concentration 
and platelet count should be reported in addition to TEG/ROTEM values to enable the 
potential impact of these factors on the TEG/ROTEM results to be evaluated. 
Future Studies: Further investigation, using a reliable thrombosis endpoint, in veterinary 
species to better define hypercoagulability based on TEG/ROTEM parameters is clearly 
required. 
 
Worksheet Question: How should hypocoagulability be defined? 
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Conclusions: There is insufficient evidence to recommend how hypocoagulability should 
be defined in companion animals based on TEG/ROTEM parameters at this time. We 
suggest that individual studies report sufficient data on patients and controls to enable 
definitions of hypocoagulability to be evaluated post-hoc. We recommend that all studies 
specifically report how hypocoagulability was defined. We suggest that use of multiple 
TEG/ROTEM derived parameters in combination may increase specificity for 
identification of subsets of hypocoagulability. We recommend that all 4 standard 
TEG/ROTEM variables are universally reported to enable meta-analysis to be conducted 
in future. We recommend that values for hematocrit, fibrinogen concentration and platelet 
count be reported in addition to TEG/ROTEM results. 
Summary of Evidence: Evidence from three studies in dogs (LOE 2 and 4, Good),6, 20, 25 
and 1 study in horses (LOE 2, Good),8 suggest that a suitable universal definition for 
hypocoagulability cannot be determined at this time. Present literature provides evidence 
that trends in variables indicating hypocoagulability include increased R/CT or K/CFT 
values and/or decreased MA/MCF or G/MCE values. Studies in non-target species (LOE 
6, Good-Fair),33, 34 suggest that combinations of TEG/ROTEM parameters to identify 
hypocoagulability may provide superior predictive ability for bleeding; and that ROC curve 
analysis of individual parameters to identify cut-off points with associated sensitivity and 
specificity values may improve our quantification of bleeding risk. Only one of the 
aforementioned veterinary studies prospectively evaluated how tissue factor (TF) activated 
TEG correlated to clinical signs of bleeding in dogs compared to a routine coagulation 
profile.6 TEG correctly identified dogs with clinical signs of bleeding with a positive 
predictive value (PPV) of 89% and a negative predictive value (NPV) of 98%. Whereas, 
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coagulation profiles had a PPV between 50-81% and a NPV between 92-93%, depending 
on the observer. It is noteworthy that underlying disease processes contributing to blood 
loss were varied. As previously mentioned, evidence from multiple studies in companion 
animals and humans (LOE 2-6, Good-Fair),26-32 suggests that hematologic variables in 
particular hematocrit, fibrinogen concentration and platelet count significantly affect the 
results of TEG/ROTEM assays. As such, these values must be considered when defining 
hypocoagulability in particular patient populations, e.g. dogs with IMHA. Values for 
hematocrit, fibrinogen concentration and platelet count should be reported in addition to 
TEG/ROTEM values to enable the potential impact of these factors on the TEG/ROTEM 
results to be evaluated. 
Future Directions: Further investigation is clearly needed to better define 
hypocoagulability using TEG/ROTEM parameters based on their correlation with signs of 
spontaneous or surgically induced hemorrhage. 
 
Worksheet Question: Should the coagulation index, CI value, be reported and if so, what 
formula should be used? 
Conclusions: There is currently insufficient evidence to make a recommendation regarding 
use of CI in companion animals. We suggest that the CI equation derived for humans is not 
used for companion animals (CI = –0.245R + 0.0184K + 0.1655MA – 0.0241 – 5.0220). 
We suggest that the CI equation derived for dogs may be considered for use in that species 
(CI = 0.1227R + 0.0092K + 0.1655MA – 0.0241 – 5.0220).35 We recommend that all 4 
standard TEG/ROTEM variables (R, K, α, MA / CT, CFT, , MCF) are universally 
reported to enable calculation of a coagulation index post-hoc if required.  
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Summary of Evidence: Based on 5 articles reviewed (LOE 4-6, Fair-Poor),32, 35-38 of which 
none completely addressed the worksheet question, recommendation for using CI in 
addition to, or in place of, other TEG parameters cannot be made. Two veterinary studies 
utilized CI as a variable. One study involving IMHA in dogs found an association between 
a normal CI and decreased survival but was retrospective in nature and necropsies were 
not performed.35 The CI formula used was reported to be canine in origin, produced with 
recalcified, non-activated, citrated whole blood, and although a review paper was 
referenced, the derivation was not provided.39 The second study documented 
hypercoagulability in patients with renal failure and protein-losing nephropathy, with 
increased CI as a supportive variable.32 The CI formula used was the human derivation 
produced with recalcified, non-activated, citrated whole blood. 
Thus, although a canine specific coagulation index equation has been generated, 
the methodology for this derivation was not reported and the applicability or potential 
benefits of this canine specific equation are unknown at this time. The extension of the CI 
equation derived for humans to canine patients has also not been validated and as such its 
use is not recommended. Provided all 4 standard TEG variables (R, K, , MA) are reported 
in both healthy individuals and those under study the CI could be calculated post-hoc if 
necessary. It is prudent to keep in mind that, as discussed in other sections, TEG and 
ROTEM are affected by many variables and reference intervals are unique to the activator 
and laboratory protocol. Coagulation index is dependent upon these output variables and 
likely influenced by the same factors.  
Future Directions: Studies directly evaluating the clinical utility of species and activator 
specific CI in animals compared to non-viscoelastic based outcomes are needed. 
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Worksheet Question: Which fibrinolysis parameters should be reported? 
Conclusions: There is currently insufficient data in companion animals to recommend 
reporting of specific fibrinolytic variables. We suggest that the TEG variables Ly30, Ly60, 
CL30, CL60 and the ROTEM variables LI30, LI60, ML, LOT and LT be universally 
reported to enable meta-analyses to be conducted in the future. 
Summary of Evidence: Few companion animal publications exist regarding the 
measurement of fibrinolysis using TEG or ROTEM.40, 41 While numerous variables exist 
for the reporting of clot lysis, there does not appear to be consistency in the values reported 
in literature involving human subjects.42-68 
 In thromboelastography, the percentage reductions in the tracing amplitude at a 
specified amount of time (e.g. 30 or 60 minutes) after maximum amplitude is measured 
(Ly30 and Ly60) are commonly reported measures of fibrinolysis.40, 41, 44, 47, 58, 69 Similar to 
these measurements, the clot lysis index (CL30 and CL60) is the amplitude of the tracing 
at a specific time point divided by the maximal amplitude, expressed as a percentage.41, 49, 
55 Another less commonly reported TEG value which describes fibrinolysis is the estimated 
percentage lysis at 30 minutes after MA (EPL), which is an estimated value based on the 
contour of the tracing immediately following the maximum amplitude.47 
 In comparison with these TEG measurements, ROTEM offers additional variables 
that describe fibrinolysis. The lysis index (LI30 and LI60) is the variable that represents 
the clot firmness remaining after a specified amount of time after the first appearance of a 
clot (CT) as a percentage of the maximum clot firmness (MCF).52, 56 The variable ML 
indicates the maximum amount of lysis occurring throughout the ROTEM analysis, 
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expressed as a percentage of MCF.52 Two additional variables that describe the rate of 
fibrinolysis are lysis onset time (LOT), the amount of time following MCF needed for clot 
firmness to decrease by 15%, and lysis time (LT), the time needed for clot firmness to 
decrease by 90% following the MCF.52 Also, a separate assay called APTEM can be 
performed in which an inhibitor of fibrinolysis, aprotinin, is added to the sample. The 
results of this test can then be compared to standard assays (e.g. EXTEM) to verify 
recovered clot stability with the addition of aprotinin.70 
Future Directions: Studies are needed in animals with true disease positive and disease 
negative status (hyper- or hypofibrinolysis) defined by non-viscoelastic methods to 
determine which, if any, TEG/ROTEM variables are clinically relevant. Studies are also 
needed which document normal values in healthy animals. 
 
Worksheet Question: How should hyperfibrinolysis be defined? 
Conclusions: There is insufficient evidence to recommend how hyperfibrinolysis should 
be defined in companion animals based on TEG/ROTEM parameters at this time. We 
suggest that individual studies report sufficient data on patients and controls to enable 
definitions of hyperfibrinolysis to be evaluated post-hoc. We suggest that the TEG variable 
(Ly30, Ly60, CL30, CL60) and the ROTEM variables (LI30, LI60, ML, LOT and LT) be 
universally reported to enable meta-analyses to be conducted in the future. 
Summary of Evidence: Only 1 veterinary publication was identified that was able to 
demonstrate the utility of TEG to document hyperfibrinolysis in companion animals (LOE 
5, Poor).40 In contrast, there is a large body of human literature which focuses on 
identifying hyperfibrinolysis in patients with trauma, brain surgery, liver transplantation, 
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and other disease states using both TEG and ROTEM (LOE 6, Good-Poor).42-63 
Hyperfibrinolysis may be defined by changes in several TEG and ROTEM variables. It 
may be represented in TEG by an increase in Ly30 or Ly60, decrease in CL30 or CL60, or 
an increase in EPL. In ROTEM, hyperfibrinolysis may be detected by a decrease in LI30 
or LI60, increase in ML, decrease in LOT, or decrease in LT. APTEM may also be 
beneficial for the confirmation of hyperfibrinolysis in standard INTEM or EXTEM assays. 
Future Directions: Studies are needed to correlate these variables with hyperfibrinolytic 
states, documented with non-viscoelastic based technology, to determine which are the 
most clinically relevant values.  
 
Worksheet Question: How should hypofibrinolysis / resistance to fibrinolysis be defined? 
Conclusions: There is currently insufficient data in companion animals to recommend use 
of specific variables to define hypofibrinolysis. Standard TEG/ROTEM assays may be 
unable to detect hypofibrinolysis in companion animals. 
Summary of Evidence: Changes in TEG variables indicative of hypofibrinolysis include: 
decreased Ly30 and Ly60, increased CL30 and CL60, and decreased EPL. Similarly, 
ROTEM values indicative of hypofibrinolysis include: increased LI30 and LI60, decreased 
ML, and increased or unmeasurable LOT and LT. Despite the widespread usage of TEG 
and ROTEM in veterinary medicine, variables describing fibrinolysis in canine and feline 
blood samples are infrequently reported. Three separate validation studies for 
thromboelastography in dogs (LOE 3, Good),10, 14, 15 do not include data pertinent to 
fibrinolysis. A study comparing 3 methods of activation for TEG in healthy cats (LOE 3, 
Good),12 described median and range values for Ly30 and Ly60. As described in this 
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manuscript, range values for Ly30 and Ly60 in normal cats reach as low as 0%. Similarly, 
reference intervals for Ly30 and Ly60 in dogs also reach 0% at the lower limit (LOE 5, 
Poor).40 In the 1 study published in horses describing hypofibrinolysis in patients with acute 
gastrointestinal disease, reference intervals for Ly30 and CL30 extend to 0% and 100%, 
respectively (LOE 2, Fair).41 As such, standard TEG and ROTEM assays appear to be 
unable to detect hypofibrinolysis in companion animals. The development of modified 
TEG models, which involve the addition of a fibrinolytic stress, e.g. tissue-plasminogen 
activator (t-PA), may better identify hypofibrinolysis.66 A recent publication (LOE 2, 
Good) describes the usage of a t-PA-modified TEG analysis in a cohort of 20 dogs with 
diseases typically associated with thrombosis.71 After applying t-PA, the lowest median 
lysis levels were in dogs with systemic inflammation and protein-losing disorders. Using a 
threshold below the lower end of the range of the healthy control group, more than 50% of 
the diseased dogs had Ly30 and Ly60 values consistent with hypofibrinolysis. 
Future Directions: Studies are needed to correlate these variables with hypofibrinolytic 
states, documented with non-viscoelastic based technology, to determine the most 
clinically relevant data to report.  
 
Worksheet Question: Should each center define its own TEG/ROTEM reference intervals? 
How should TEG/ROTEM reference intervals be defined? 
Conclusions: We recommend that every center using TEG/ROTEM should establish its 
own reference interval using established veterinary clinical pathology guidelines. We 
recommend that reference intervals for TEG and ROTEM are not interchangeably used. 
We recommend that only appropriately trained operators be involved in establishing 
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reference intervals for TEG/ROTEM. We recommend that age and breed be considered 
when establishing reference intervals for TEG/ROTEM. We recommend that sample 
collection, sample handling and assay protocols be standardized when establishing 
reference intervals for TEG/ROTEM. 
Summary of Evidence: Multiple studies (LOE 2-6, Good-Fair),10, 11, 14, 15, 72-86 have reported 
methods for calculation of TEG/ROTEM reference intervals. No identified study 
specifically addressed the worksheet question, however, multiple analytical and pre-
analytical factors have been shown to influence TEG results in companion animals and in 
people, suggesting that due consideration to such variables should be given when 
establishing reference intervals. The reader is referred to the first three sections of these 
guidelines for further information on this subject. Guidelines from non-target species (LOE 
6, Good),87 suggest that at least 40 individuals are required for accurate calculation of 
reference intervals based on the 2.5-97.5th percentiles. Evidence based guidelines for 
establishment of reference intervals in veterinary clinical pathology have recently been 
published by the American College of Veterinary Clinical Pathology and provide detailed 
guidance on methods for defining reference intervals.a Based on these guidelines, it is 
further recommended that direct sampling methods are used a priori, in which inclusion 
and exclusion criteria are established prior to selection of healthy reference animals, which 
should be deemed normal based on physical examination and blood work, including 
hematocrit, fibrinogen concentration and platelet count for reasons previously discussed. 
Data collected from less than 20 animals should not be reported as reference intervals.88 
Although data collected from between 20-40 animals may be used for reference interval 
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generation, they should be tested for normality and then appropriate robust or parametric 
methods used for RI calculation.88  
 
Worksheet Question: What is the potential benefit of Vcurve data compared to 
conventional TEG parameters? Should TEG publications report Vcurve data and if so, 
which values? 
Conclusions: There is currently insufficient data in companion animals to suggest a utility 
for Vcurve variables beyond that of standard TEG variables. We suggest that universal 
reporting of Vcurve parameters of the TEG curve in companion animals is not required at 
present. We suggest however, that authors consider reporting Vcurve data in addition to 
standard TEG variables in order to increase the amount of data available for review. 
Summary of Evidence: Thrombus velocity curves (Vcurve) are plotted from the first 
derivative of the waveform generated by the TEG system and are expressed as changes in 
clot tensile strength per unit of time (dynes/cm2/s), representing the maximum velocity of 
clot formation.b Vcurve derivatives include the ‘time to maximum rate of thrombus 
generation’ (TMRTG), ‘maximal rate of thrombus generation’ (MRTG), ‘total thrombus 
generated’ (TG), ‘time to maximal rate of lysis’ (TMRL), ‘maximum rate of lysis’ (MRL) 
and ‘total lysis’ (L). These computed parametric derivatives enable quantification of the 
kinetics of clot propagation and they have been suggested to represent surrogate markers 
of thrombin generation (LOE 6, Good-Poor).89, 90 Vcurve parameters cannot be calculated 
from the standard TEG parameters but only obtained by analysis of the velocity curve 
generated at the time the TEG was performed. Therefore, if a study does not report Vcurve 
parameters, that information (if later shown to be useful) would involve authors going back 
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to the original output generated by the TEG analyzer, which would prove logistically 
difficult.  
 Twenty-one peer-reviewed manuscripts (LOE 2-6, Good-Poor) 3, 25, 86-103 fulfilled 
the search criteria by reporting TEG Vcurve data. Several of the studies (LOE 6, Good-
Poor), 3,25, 86,87,91-95,99,102,103 all in non-target species, provide evidence in support of using 
Vcurve variables to further delineate the hemostatic abnormalities. Support for using these 
data occur in the context of direct thrombin inhibitor administration,99 antiplatelet drug 
administration,92 liver transplantation,91 transfusion effectiveness,91 parturition,93,94 critical 
illness,3 and hemophilia.103 Some studies were more methodological and showed a 
correlation between Vcurve variables and platelet count,25 and one study demonstrated that 
both standard TEG and Vcurve variables are, not surprisingly, affected by timing of 
initiation of analysis.102  
Several studies (LOE 2-6, Fair-Poor)88-90,97,98 were neutral in support of using 
Vcurve data in addition to standard TEG variables. One veterinary study (LOE 2, Fair)88 
evaluated the ability of TEG Vcurve variables to highlight deficiency in procoagulant 
activity in Scott syndrome. Although the TMRTG was prolonged in dogs with the defect, 
there was too much overlap with unaffected dogs for this to be considered useful from a 
diagnostic standpoint, and other methods, such as flow cytometry, were superior in their 
diagnostic capability. A second study in dogs (LOE 2, Fair)89 examined standard TEG and 
Vcurve variables in dogs with primary immune-mediated hemolytic anemia. Although 
there were some significant changes, conflicting data were generated that cannot be easily 
explained. The third canine study (LOE 3, Poor)90 sought to determine if dogs with 
carcinoma had Vcurve evidence of hypercoagulability by evaluating the TTG variable. 
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While dogs with tumors did have higher mean TTG compared with controls, there appeared 
to be much overlap in values with control dogs. Furthermore, thrombin-antithrombin 
complexes were not significantly different between the groups, which would suggest that 
thrombin generation was not increased, if this is considered the gold standard.  
The time from sample collection to onset of testing, mode of activation, and sample 
matrix, all vary dramatically between the aforementioned studies making it difficult to 
draw any conclusions. Based on evidence from 3 studies performed in dogs (LOE 2-3, 
Fair-Poor),92-94 universal reporting of Vcurve parameters in publications reporting TEG 
analysis cannot be supported at the present time. As regards the specific Vcurve parameters 
that may prove to be most useful MRTG, TMRTG and TG were identified.  
Future Directions: Investigations are needed to test the aforementioned Vcurve parameters 
against validated, independent (i.e. not TEG-derived) markers of clot formation kinetics 
such as the calibrated automated thrombogram.95 
 
Footnotes 
a http://www.asvcp.org/pubs/pdf/RI%20Guidelines%20For%20ASVCP%20website.pdf 
b TEG 5000 User’s Manual, Haemoscope, part of Haemonetics Corporation, Braintree, 
MA. 
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